The diagnosis and treatment of hepatocarcinoma (HCC) is believed to be improved due to the development of specific targeting probes by molecular imaging methods. GPC3, which is a hepatocellular carcinoma (HCC)-specific tumor marker, anchors at most HCC cells. To target this cell membrane protein, we developed a novel nanoparticle by conjugating WS 2 -Ga 3+ -PEG and a short peptide with favorable specificity and affinity to the GPC3 protein.
Hepatocellular carcinoma (HCC) is the most common liver malignancy and the third most frequent cause of cancerrelated death worldwide [1] . Owing to its high invasiveness and latent clinical manifestation, most of the patients with HCC are diagnosed during the mid or late stage without surgery opportunities, leading to a poor prognosis. The current diagnostic methods involve serological examination, traditional imageological examination and biopsy examination; however, they have some limitations. The alpha-fetoprotein (AFP, prevalent tumor marker) test, which is employed as a clinical screening test, lacks sufficient sensitivity and specificity. The traditionally enhanced spiral CT scanning and MRI also lack specificity because it is difficult to compare liver tumor enhancement patterns at various time points after intravenous contrast medium administration [2] . Furthermore, in some cases, they cannot distinguish between a liver cirrhosis nodule and a small HCC [3] . Furthermore, invasive examination techniques, such as digital subtraction angiography and biopsy test, are time consuming [4] and increase tumor-seeding risk [5, 6] . Therefore, a sensitive and specific approach is required to diagnose HCC at an early stage, improve the prognosis and reduce morbidity.
Recently, GPC3 was identified as a biomarker and therapeutic agent for HCC. According to a study, 72% of the HCCs express GPC3; however, this protein is not detected in normal hepatocytes, cirrhotic liver or benign lesions [7] . Unlike AFP, which has high false-positive rate (14.3-35 .0%) in benign liver diseases, some studies have recommended a combination of circulating GPC3, GPC3 mRNA and AFP to improve the accuracy of HCC diagnosis and have reported ideal outcomes [8, 9] . In clinical biopsy, immunohistochemical study with GPC3 has been used to confirm the pathological diagnosis of HCC, when it is difficult to differentiate malignant liver lesion from benign lesion.
GPC3 is a member of the glypican family of proteoglycans that are attached to the cell surface by a glycosylphosphatidylinositol anchor [10] . It has been shown that mutations in GPC3 or knockdown of its function can inhibit HCC growth, demonstrating the significant role of GPC3 in the development of HCC [11, 12] . Furthermore, the GPC3 protein anchors to the cell membrane and therefore can specifically combine with nanoparticles. Thus, the administration of a probe that specifically binds to the GPC3 protein can exclusively target the HCC cell during diagnosis and therapy. A recent study has reported that anti-GPC3 antibody [13] and αGPC3-F(ab )2 fragments can be used to target GPC3 [14] . Although the monoclonal antibody has high affinity to GPC3 [13] , the large size of the anti-GPC3 antibody and αGPC3-F(ab )2 fragments might have negative effects, such as suboptimal imaging pharmacokinetics, poor tumor penetration and increased immunogenicity [15, 16] . To address these problems, we used a peptide [17] that was identified by screening a phage display peptide library; the specificity and affinity of the peptide to GPC3 have been demonstrated. Peptide-based molecular imaging probes have the following advantages: low molecular weight, ease of modification and low cost for scale up [18] . Furthermore, the phage display peptide library has been proven to be an effective tool to identify protein-binding ligands by screening with purified targets [19] .
Transition metal dichalcogenides (TMDCs), with metal and chalcogen atoms, have been explored in various fields. Its application in the field of biomedicine is promising [20, 21] . Certain types of TMDCs, such as WS 2 and Bi 2 Se 3 , can be utilized as a computed tomography agents [21] . Furthermore, to enable its use in MRI, a magnetic element can be attached to TMDCs [22] .
Photoacoustic imaging (PAI) is a novel technology that largely overcomes the spatial resolution and depth limits of traditional optical imaging. Various PA agents have been developed for medical research [23, 24] ; TMDCs also have potential to be an ideal PA agent [25, 26] . Herein, utilizing the paramagnetic property of Ga 3+ and strong near-infrared region (NIR) absorbance of WS 2 , we synthesized an MRI and PAI bimodal nanosheet. To acquire satisfactory magnetic resonance (MR) and PA imaging effects simultaneously, we fabricated the new nanosheet by the bottom-up method; we used this method to dope with the Ga element in a ratio of our interest. Furthermore, peptide that specifically targets the GPC3 protein was adhered to the nanosheet, resulting in a HCC targeting nanosheet WS 2 -Ga 3+ -PEG-peptide. Photothermal therapy (PTT) usually employs NIR light-absorbing agents to generate heat from optical energy, causing thermal ablation of cancer cells [27] [28] [29] . Furthermore, TMDC was first demonstrated as a PTT agent for in vitro photothermal ablation of cancer cells at the cell culture level in 2013 [30] . Subsequently, successive studies on TMDCs for PTT ablation of cancer in vitro and in vivo have been carried out [25, 26, 31] . However, the in vivo applications of TMDCs, particularly its conjugation with certain tumor ligands to increase its specific targeting ability, remain unexplored. Furthermore, the PTT effects after systemic administration of TMDCs have to be evaluated.
Materials & methods

Synthesis & modification of the nanosheet
A mixture of WCl 6 and GaCl 3 (1 mmol) in the ratio of 7:3 was mixed with 20 ml of oleylamine and 10 ml of 1-octadecene in a 50 ml three-necked flask. The flask was heated at 150
• C for 30 min by magnetic stirring with nitrogen protection to remove water and oxygen. Subsequently, the temperature was increased to 300
• C, and the solution was incubated for 30 min with nitrogen protection. Sulfur (S) solution was prepared by dissolving 2 mmol S powder in 5 ml oleylamine. This solution was then slowly added to the reaction mixture and incubated for another 30 min at 300
• C. The solution was then cooled to room temperature and approximately 30 ml anhydrous ethanol was added to precipitate the nanosheet. Hexane was used to disperse the nanosheets and to remove oleylamine. For PEGylation of the nanosheets, the nanosheets in hexane were added to water-containing excess of NH 2 -PEG-COOH in a beaker and stirred overnight using a magnetic stirrer. The nanosheets were collected by centrifuging the solution to remove the supernatant; the nanosheets (WS 2 -Ga 3+ -PEG) were soluble in water. To link the peptide to WS 2 -Ga 3 +-PEG, the nanosheets and peptide were mixed in a molecular ratio of 2:1 and oscillated overnight. WS 2 -Ga 3+ -PEG-peptide was collected after centrifuging the mixture to remove the supernatant.
Characterization of the probe
The microstructure of the probe was obtained by TEM (JEM-1011, JEOL Co. Ltd, Japan). The absorbance spectra of the probe were obtained using an UV-Vis-NIR spectrophotometer. Using specific spectra, the stability in fetal bovine serum (FBS) (Gibco Corporation, NY, USA), phosphate-buffered saline (PBS) and culture media (DMEM, Gibco Corporation) was determined by testing the variation in spectra after incubating the serum for different periods (0, 6, 12, 24 and 48 h). The MR signal intensity of the probe at different concentrations (0, 1, 2, 3 and 5 mg/ml) was measured. Similarly, the PA signal intensity of the nanosheets was measured by subcutaneously injecting the mice with different concentrations (0.1, 1.1, 2.2 and 5.5 mg/ml) of WS 2 -Ga 3+ -PEG-peptide. To explore the PTT efficiency of WS 2 -Ga 3+ -PEG-peptide, different concentrations of nanosheet (100, 300 and 500 μg/ml) were exposed to a 808-nm laser beam of intensity 2 W/m 2 for 5 min, and the temperature variation was recorded using an IR thermal camera (Ti27, FLUCK, WA, USA).
Cell culture experiment
The HepG2 murine HCC cell line was cultured in DMEM (Gibco Corporation) at 37
• C in a 5% CO 2 atmosphere. For toxicity assay, the cells were seeded in a 96-well plate and cultured for 24 h to obtain a density of 1 × 10 4 cells per well. Different concentrations of WS 2 -Ga 3+ -PEG-peptide were then added into the wells and the plate was incubated for another 24 h. The CellTiter 96 R AqueousOne solution (Promega Biotech Co. Ltd, Beijing, PR China) was then added to the wells, and the plate was incubated for 4 h according to the standard protocol to determine the number of viable cells, which was measured using a multimode microplate reader (Biotec Synergy™, VT, USA). To test the uptake of the probe, WS 2 -Ga 3+ -PEG-peptide and PBS were individually incubated with the HepG2 cells for a certain time. The cells were then washed with PBS, and the uptake of the nanosheet was quantified using a multimode microplate reader at different periods of co-incubation using the specific NIR spectrum of WS 2 -Ga 3+ -PEG-peptide. For in vitro PTT assay, the HepG2 cells cultured in 96-well plate were exposed to 808-nm NIR laser beam (Hi-Tech Optoelectronics Co, ChangChun, China) of different power intensities (0.4, 0.8, 1.2, 1.6 and 2.0 W/m 2 ) for 24 h after incubation with PBS and 100 μg/ml WS2-Ga 3+ -peptide, respectively. The MTT assay (the method using 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide to detect cell growth) was also conducted after the PTT assay, stained with calcein AM for 15 min and imaged using a fluorescence microscope (Leica M205F, Leica Microsystems Inc., Buffalo Grove, Gemany) to determine cell viability.
Tumor model
Balb/c nude 5-6-week-old male mice were obtained from the Vital River Corporation (Beijing, China). The subcutaneous HepG2 tumor-bearing mice were obtained by the subcutaneous injection of 1 × 10 6 HepG2 cell suspension onto the back of each mouse. The orthotopic HepG2 liver tumor-bearing mice were obtained by injecting 1 × 10 6 cells in 30-50 μl suspension mixed with matrigel (Basement Membrane Matrix, Growth Factor Reduced, Phenol Red-free, BD Biosciences, NJ, USA) into the hepatic subcapsular space of the liver. The HepG2 cell-bearing mice were randomly divided into two groups. Control group: intravenous (iv.) injection of PBS (n = 5); test group: iv. injection of WS 2 -Ga 3+ -PEG-peptide (n = 5). To explore the biodistribution of WS2-Ga3+PEG-peptide, we conjugated the fluorescent dye Cy5.5 with the probe and monitored the changes in the whole-body image using the IVIS system (IVIS Spectrum, Perkin Elmer Co. Ltd, AZ, USA) after the intravenous administration of nanosheets into the tumor-bearing BALB/c mice. To evaluate the diversity in tumor homing property of WS2-Ga3+PEG-peptide and WS2-Ga3+PEG in vivo, both the nanosheets were administrated to the mice and their biodistribution was determined.
In vivo MRI & PAI T1-weighted MRI imaging was conducted using the BioSpec 94/30 USR (BRUKER Corporation, Germany) with a small animal coil. T1-weighted MRI was carried out with the following parameters: slice thickness, 0.8 mm; slice spacing, 0.1 mm; matrix, 256 × 256; and FOV, 2.2 cm × 2.2 cm. PAI was performed by multispectral optoacoustic tomography (MOST) version 128 (iThera Medical Company, Munich, Germany). The HepG2 cell-bearing mice were iv. injected WS 2 -Ga 3+ -PEG-peptide (200 μl, 2 mg/ml) 24 h before the MR and PA scans. The quantified MR T1-weighted relaxivity and PA signal intensity in the tumor region were compared between the test and control groups.
In vivo PTT therapy 24 hours after the iv. injection of WS 2 -Ga 3+ -PEG-peptide (200 μl, 2 mg/ml), all the mice were subjected to PTT with a 808-nm NIR laser beam of intensity 2 W/m 2 for 5 min; a same dose of PBS was injected to the mice in the control group. The temperature during the PTT procedure was measured using an IR thermal camera (Ti26, FLUCK Corporation). The length and width of the tumor were measured every 2 days using a caliper to calculate the tumor volume as: volume = [length × (width) 2 ] / 2. In addition, 10 days after treatment, tumor tissues from the PTT group and postablation tissues from control group were dissected to prepare paraffin sections for haematoxylin and eosin (H&E) staining by standard protocol for pathological examination using a microscope (Leica).
Results & discussion
The physical properties of WS 2 -Ga 3+ -PEG-peptide are shown in Figure 1 . The absorbance spectra was high ranged with wavelengths of 700-1000 nm in the NIR spectra. The absorbance peak was approximately at 954 nm ( Figure 1A ). Following incubation with FBS, PBS and culture medium for 48 h, the absorbance spectra of the probe still persisted within the original curve and in the stable absorbance unit (Supplementary Material 3) . This indicates that the probe was physically stable in FBS, PBS and culture medium, thus presenting a favorable biological compatibility that can be employed in subsequent experiments. The TEM showed a typical WS 2 -Ga 3+ -PEG-peptide of diameter 100 nm ( Figure 1D ). Dynamic light scattering was performed to examine the size of the probe at 124.8 ± 20.73 nm (Supplementary Material 4) . The results revealed that the probe dissolves in water effectively.
A high absorbance in a wide spectral range in NIR indicates that the probe has a potential to be used as a photothermal therapy (PTT) agent that is irradiated by a laser beam of wavelength 808 nm. An obvious concentration-dependent increase in temperature was observed, and the real-time temperature data were recorded using an IR thermal camera ( Figure 1C ). The temperature of WS 2 -Ga 3+ -PEG-peptide in the highest concentration solution (500 μg/ml) reached up to 40
• C from normal room temperature within 5 min. In comparison, the PBS solution exposed to similar photothermal condition maintained the room temperature. This proved that WS 2 -Ga 3+ -PEG-peptide is an excellent PT agent. PAI is a new molecular imaging technique that has gained significant interest. It is expected to have broad applications in biomedical treatment [32] , especially in tumor diagnosis, due to enhanced imaging penetration depth as well as spatial resolution [33] . It can detect hemoglobin, lipids and other light-absorbing agents. Therefore, the high vessel density in tumors can be identified clearly, especially when high light-absorbing agents accumulate in the tumor [34] .
Herein, we investigated the use of WS 2 -Ga 3+ -PEG-peptide as a PA agent because of its high NIR absorbance. After the subcutaneous injection of different concentrations of the nanosheet onto the back of the mice, the intensity of PA signal was measured and calculated by MSOT. It is thought to be more persuadable than that measured in a certain container because the test was conducted in live animal. As shown in Figure 1E , the intensity of PA signal enhanced sharply with increase in concentration. Thus, the WS 2 -Ga 3+ -PEG-peptide might be a promising contrast agent for PAI.
MRI is one of the most commonly used imaging tools for clinical tumor diagnosis due to its high resolution. Agents containing paramagnetic Gd 3+ are popular as a T1 contrast in MRI. To explore the possibility of WS 2 -Ga 3+ -PEG-peptide as an MRI agent, the T1-weighted relaxivity was measured with different concentrations of WS 2 -Ga 3+ -PEG-peptide. An obvious concentration-dependent increase in T1 relaxivity was observed ( Figure 1F ). WS 2 -Ga 3+ -PEG-peptide exhibited excellent imaging effect both in MRI and PAI, at an optimal ratio of WS 2 :Ga 3+ . If the proportion of Ga 3+ was too high, it affected the PAI and PTT effects. On the contrary, if the proportion of Ga 3+ was too small, the MRI effect was not satisfactory. The observed results demonstrated that we successfully balanced the ratio of W and Ga 3+ by the bottom-up synthesis method. The W/Ga ratio of 7:3 has been reported to be an optimal ratio [26] . WS 2 -Ga 3+ -PEG-peptide qualified as an appropriate bimodal MRI and PAI agent. This will enable us to combine the advantages of both the imaging techniques, in other words, MRI to determine the macroscopic outline and location of malignancy, and PAI to provide high spatial resolution. To define the border of HCC during surgery is a medical challenge. Due to the obvious shortages in intraoperative MRI, such as relatively strict instrument requirement and the administration of high dose of Gd (which might result in false-positive enhancement), PAI will be a promising surgery navigation tool. Furthermore, the WS 2 -Ga 3+ -PEG-peptide agent has a promising application in surgery navigation; however, further in vivo examination is necessary. Meanwhile, WS 2 -Ga 3+ -PEG-peptide is an excellent PT agent and can be used for diagnosis and therapy simultaneously, providing a diversified therapy method for clinical choice.
To explore the cytotoxicity of WS 2 -Ga 3+ -PEG-peptide, standard MTT assay was carried out to determine the relative viability of the HCC cell line HepG2. After incubation with the probe at different concentrations, no significant cytotoxicity was observed even at the highest concentration of 0.1 mg/ml (Figure 2A ). For the PTT experiment, 0.1 mg/ml of WS 2 -Ga 3+ -PEG-peptide with HepG2 cells was exposed to various power intensities of H 2 O 100 ug/ml 300 ug/ml 500 ug/ml
Figure 1. Physical properties of WS 2 -Ga
3+ -PEG-peptide. The absorbance spectra of WS 2 -Ga 3+ -PEG-peptide (A); The absorbance spectra was stable even after incubating WS 2 -Ga 3+ -PEG-peptide in FBS for 48 h (B); The temperature of the probe increased in a concentration-dependent manner, when exposed to a laser beam of wavelength 808 nm. The inset picture shows the distinctive effect between PBS and the probe recorded by an IR thermal camera (C). The SEM and TEM images showed that the diameter of the probe is approximately 100 nm, the inset picture shows the shape of WS 2 808-nm laser beam for 24 h. The relative cell viability decreased starting at a power density of 1.6 W/m 2 , which was significant at 2 W/m 2 ( Figure 2B ). A similar result was also observed by the calcein AM fluorescent staining method (Supplementary Material 1) . The green spots shown in Figure 2C represent the live cells; the density of live cells decreased significantly with increase in laser power intensity. These results demonstrate that WS 2 -Ga 3+ -PEG-peptide as a PT agent is effective at a laser power intensity of >1.6 W/m 2 , especially at 2.0 W/m 2 . In the WS 2 -Ga 3+ -PEG-peptide uptake test, WS 2 -Ga 3+ -PEG-peptide was incubated with the HepG2 cells. As shown in Figure 2D , the absorbance intensity of WS 2 -Ga 3+ -PEG-peptide, tested by multimode microplate reader, was significantly higher than that of H 2 O even after co-incubation for 1 h, and the gap widened with the incubation time. This suggests that the HepG2 cells had successfully absorbed WS 2 -Ga 3+ -PEG-peptide, and the amount of probe absorbed was time dependent.
To explore the biodistribution of WS 2 -Ga 3+ -PEG-peptide and to compare it with WS 2 -Ga 3+ -PEG, the changes in the whole-body image were monitored using the IVIS system after the intravenous administration of the nanosheet. Strong fluorescent signals were emitted from the body 10 min after administration in the nanosheetadministrated mice. After 1 h, the observed fluorescent signals began to shift from the liver to tumor region and therefore the tumor tissue was distinguished from peripheral normal tissues ( Figure 2G) . However, the fluorescent signals in WS2-Ga3+PEG-peptide-administrated mice sustained significantly longer and stronger during the 48-h observation period ( Figure 2E ). This indicates that WS 2 -Ga 3+ -PEG-peptide has a tumor accumulation property stronger than that of WS 2 -Ga 3+ -PEG, due to its ability to target GPC3. Currently, the MR inspection is recognized as the first choice to diagnose HCC in clinical practice. Thus, we also conducted MR imaging of HepG2 orthotopic tumor-bearing mice (n = 5). 24 hours before the MR scan, 2 mg/ml of WS 2 -Ga 3+ -PEG-peptide (200 μg) was intravenously injected. Most of the T1-weighted MRI signals of the orthotopic tumor lesion showed no distinction before and after the injection of WS 2 -Ga 3+ -PEG-peptide. Except for one instance as shown in Figure 4 , a small (approximately 1 cm in diameter) orthotopic liver tumor was observed in the MR image after WS 2 -Ga 3+ -PEG-peptide injection. However, it was not observed before WS 2 -Ga 3+ -PEG-peptide injection, owing to the early stage of tumor development. As WS 2 -Ga 3+ -PEG-peptide efficiently adhered to the GPC3 protein on the HepG2 cells, the tumor might take up more nanosheets, thus contributing to a strong T1-weighted MRI signal. These results demonstrate that in the orthotopic liver tumor model, WS 2 -Ga 3+ -PEG-peptide successfully targeted the HepG2 cells. Furthermore, during the early stage of HCC, as the tumor size is small and tumor differentiation is relatively low, the positive rate of ordinary MR inspection might decrease. The inspection sensitivity might decrease from 82-93% [35] to 31-69%, in tumors of size <20 mm [36, 37] . In the present study, we could inspect small tumors of size approximately 1 cm after the application of novel nanosheets. Therefore, unlike the ordinary MR imaging, the novel nanosheets are promising to inspect early small HCC. However, the sample amount used in the present study was not large enough and therefore further experiments are required to focus on the application of WS 2 -Ga 3+ -PEG-peptide to detect HCC at an early stage.
Using the optical and magnetic properties of WS2-Ga 3+ -PEG-peptide, a bimodal MR/PA imaging for HepG2 tumor-bearing mice was conducted. The Balb/c nude mice-bearing HepG2 subcutaneous tumor were intravenously injected WS 2 -Ga 3+ -PEG-peptide (2 mg/ml; 200 μl), and then imaged 24 h after injection using the BRUKER BioSpec 94/30 USR MR and iThera MSOT version 128 PA instrument. A high tumor contrast was observed after WS 2 -Ga 3+ -PEG-peptide injection both in MR and PA imaging ( Figure 3A & B) . The MR signal intensity increased from 5065.8 ± 517.3 to 9375.6 ± 528.2 and the PA signal intensity increased from 69.6 ± 1.75 to 142.4 ± 3.3. The quantified data is presented in Figure 3C . The results of in vivo imaging demonstrated that WS 2 -Ga 3+ -PEG-peptide possessed selectively targeted HepG2 tumor after its systemic administration and therefore is a promising ideal contrast agent for MRI and PA imaging.
After the administration of WS 2 -Ga 3+ -PEG-peptide into the HepG2 subcutaneous tumor-bearing mice, the location and spatial structure of the tumor appear to be clear and precise in the MR and PA images. Supported by the ideal imaging effect, high tumor accumulation, high NIR absorbance and strong PTT efficacy of WS 2 -Ga 3+ -PEG-peptide in in vitro experiments, we carried out in vivo PTT experiment. The subcutaneous HepG2 tumor-bearing mice were divided into two groups. The mice of the control group (n = 5) and test group (n = 5) were injected with PBS and WS 2 -Ga 3+ -PEG-peptide, respectively, and then exposed to 808-nm NIR laser beam at a power density of 2 W/m 2 for 5 min. In the test group, the tumor was completely eliminated 24 h after PTT, leaving black scars at the surface of tumor site ( Figure 5A ). Based on the variation in the size of the subcutaneous tumor measured for 10 days after PTT, no tumor recurred during the observation period ( Figure 5B) . Furthermore, the weight of the mice, measured 10 days after PPT, increased gradually in the test group as the tumor was inhibited by PPT. However, the mice in the control group lost weight due to loss of appetite with a gradual increase in tumor (Supplementary Material 2). Antitumor efficacy was assessed by H&E staining the pathological slices. The tumor cells from the test group showed severe damage as evidenced by changed cell shape, increased vacuoles and condensed nuclei in the micrograph ( Figure 5C ). However, in the PBS-injected mice, the tumor volume increased gradually and H&E-stained slices showed no significant tumor damage signs. The PPT affected only the growth of tumor without causing much damage to the normal tissues because WS 2 -Ga 3+ -PEG-peptide can selectively target tumors via active tumor homing [28] , but with little retention in normal tissue. It induced PPT effect with near-infrared light irradiation to kill cancer cells. The results suggest the excellent PTT efficacy of WS 2 -Ga 3+ -PEG-peptide, illustrating that it is a powerful agent for in vivo photothermal ablation of HCC.
Conclusion
In summary, we have successfully developed a novel photothermal thermostatic agent based on the TMDCs, which specifically targets HCC, by conjugating the HCC membrane protein GPC3 homing ligand on the nanosheets. It is found that WS 2 -Ga 3+ -PEG-peptide exhibits favorable compatibility in the physiological environment and shows no observable toxicity in vitro and in vivo. In addition, it can serve as an excellent MR and PA imaging agent. MRI imaging is used to determine the macroscopic outline of the tumor; PAI can further provide high spatial resolution and distribution information of nanosheets. In vivo PTT experiment showed that WS 2 -Ga 3+ -PEG-peptide is a highly effective photothermal agent, exhibiting excellent NIR-induced tumor ablation effect. It is promising as an ideal nanomaterial for HCC diagnosis and therapy. 
Summary points
• Novel sensitive and specific approaches are required for an early diagnosis of hepatocellular carcinoma by addressing the shortcomings of the traditional diagnosis methods.
• The in vivo applications of transition metal dichalcogenides, particularly its conjugation with a certain tumor ligand to increase its specificity, have not been explored.
• The novel nanosheet WS 2 -Ga 3+ -PEG-peptide is an ideal photothermal agent because of its high absorbance in a wide spectral range in near-infrared region.
• WS 2 -Ga 3+ -PEG-peptide exhibited favorable compatibility in the physiological environment and showed no observable toxicity in vitro and in vivo.
• WS 2 -Ga 3+ -PEG-peptide exhibited excellent imaging effect in MRI and photoacoustic imaging; it was synthesized by the bottom-up method with an optimal ratio of W:Ga.
• WS 2 -Ga 3+ -PEG-peptide showed a tumor accumulation property stronger than that of WS 2 -Ga 3+ -PEG, as it specifically targeted GPC3.
• Small tumor of size 1 cm was inspected after the administration of the nanosheets, suggesting that the nanosheet has an application in the diagnosis of hepatocellular carcinoma at an early stage.
• In in vivo photothermal therapy contrast experiment, WS 2 -Ga 3+ -PEG-peptide exhibited an excellent near-infrared region-induced tumor ablation effect. No writing assistance was utilized in the production of this manuscript.
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